PPV: Pneumococcal Polysaccharide Vaccine in Older Adults

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE4

Total Enrollment

100 participants

Study Classification

INTERVENTIONAL

Study Start Date

2001-04-30

Study Completion Date

2012-08-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to measure how long the improvement in the immune system lasts in older people after they have been vaccinated, and to examine the immune response in older people who get vaccinated a second time.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Safety and Immunogenicity Study of 23-valent Pneumococcal Polysaccharide Vaccine in Healthy Children, Adults and Elderly

NCT02451969

Pneumococcal Infections

COMPLETED PHASE3

Pneumococcal Adult-dose Ranging Immunization Study

NCT00169234

Pneumonia

COMPLETED PHASE1/PHASE2

Safety and Efficacy Study of Investigational Pneumococcal Vaccine in Elderly Population

NCT00307528

Prophylaxis Invasive Pneumococcal Diseases and Pneumonia

COMPLETED PHASE2

Study to Evaluate the Safety and Immunogenicity of an Investigational Pneumococcal Vaccine in the Elderly Population

NCT00327665

Infections, Streptococcal

COMPLETED PHASE1

Revaccination With PNEUMOVAX(TM) 23 in Older Adults (V110-007)

NCT00560950

Pneumococcal Infection

COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Streptococcus pneumonia is the leading cause of pneumonia the United States, estimated to cause at least 500,000 cases annually and 40,000 deaths. Interest in expanding pneumococcal vaccine administration has arisen with the increased prevalence of antibiotic-resistant S. pneumoniae, increasing numbers of people living with chronic medical conditions, and the aging population.

Extensive studies on vaccine response in older persons have been performed over the past 25 years. However, a number of issues hindered the assessment of vaccine response in older people. Recent studies indicate most healthy older people develop an initial antibody response to vaccination similar to younger cohorts, although antibody response to some serotypes may be less. Limited data suggest functional antibody will develop at least initially after vaccination in older recipients. There are no published reports describing the duration of antibody response or antibody function after revaccination in older patients.

It is difficult to predict the revaccination response and, for those with elevated pre-revaccination antibody, there may be no response to revaccination, or even a lowering of absolute antibody level. Accordingly, a well-controlled revaccination protocol in which older patients with defined vaccine history and known pre-revaccination antibody level are studied for quantitative and qualitative antibody response to revaccination is sorely needed.

The hypotheses for this study are:

1. Specific antipneumococcal antibody will remain above prevaccination level in the serum of healthy older people for up to ten years after PPV.
2. Healthy older people will have a prompt and robust vaccine response to primary vaccination with PPV.
3. The existence of antipneumococcal antibody in healthy older people who had been vaccinated with PPV \>5 years previously will not be associated with more pronounced or frequent adverse events or a reduced vaccine response rate.
4. The effect of advanced age will account for a reduced vaccine response.

Volunteers in the Baltimore Longitudinal Study of Aging (BLSA) will be asked to participate in this retrospective/prospective analysis. Two pools of participants will be recruited. The first group (Group I) will be 65 years and older who had received PPV five or more years earlier, and the second (Group II) will be decade and gender matched individuals with no prior exposure to PPV. These groups will be matched as closely as possible.

All volunteers (Groups I and II) will receive the same vaccines. In one arm they will receive PPV (for group I this will be revaccination and for group II this will be primary vaccination). In the other arm they will receive Meningococcal Polysaccharide Vaccine (MPV) (primary vaccination for both groups I and II).

Blood samples will be drawn before and after vaccination on day 0 (the day of vaccination), on day 28, and at 6 months following vaccination. Approximately six months after the last vaccination participants will be asked to complete a brief medical history update, either by telephone, by mail, or during their regularly scheduled BLSA visit. This update will continue to be performed every six months for the duration of the study.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Aging

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

1

Previously vaccinated

Group Type EXPERIMENTAL

Pneumococcal Vaccine

Intervention Type BIOLOGICAL

One time preventative vaccine

2

Never vaccinated

Group Type EXPERIMENTAL

Pneumococcal Vaccine

Intervention Type BIOLOGICAL

One time preventative vaccine

Meningococcal Vaccine

Intervention Type BIOLOGICAL

One time preventative vaccine

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Pneumococcal Vaccine

One time preventative vaccine

Intervention Type BIOLOGICAL

Meningococcal Vaccine

One time preventative vaccine

Intervention Type BIOLOGICAL

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Pneumovax Menomune

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Enrolled in the BLSA with at least 2 stored blood samples post vaccination
* 65 years old or older
* Previously vaccinated with Pneumovax at least 5 years ago or never vaccinated
* Willing to receive vaccination with pneumococcal and meningococcal injection
* Able to provide informed consent
* Has never received a meningococcal vaccine

Exclusion Criteria

* Hypersensitivity to the pneumococcal or meningococcal vaccine
* Ever received the Meningococcal vaccine
* History of non-skin cancer
* History of myeloproliferative disorder
* History of HIV
* Received a Bone Marrow Transplant
* Taking prednisone (more than 5 mg/day) or other immunosuppressive medication
* Evidence of severe liver or renal disease (serum creatine \>2.0 mg/dL or Total Bilirubin \>2.0

Minimum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes